EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 92 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,831 | -63.9% | 22,400 | -16.7% | 0.00% | – |
| Q2 2023 | $18,937 | -76.2% | 26,900 | -69.7% | 0.00% | – |
| Q1 2023 | $79,688 | -52.9% | 88,850 | -38.4% | 0.00% | – |
| Q4 2022 | $169,186 | -87.9% | 144,250 | -22.5% | 0.00% | -100.0% |
| Q3 2022 | $1,400,000 | +54.9% | 186,050 | +29.7% | 0.00% | +50.0% |
| Q2 2022 | $904,000 | -4.2% | 143,450 | +26.0% | 0.00% | 0.0% |
| Q1 2022 | $944,000 | +84.4% | 113,850 | +15.4% | 0.00% | +100.0% |
| Q4 2021 | $512,000 | -23.2% | 98,650 | -1.1% | 0.00% | 0.0% |
| Q3 2021 | $667,000 | -12.7% | 99,750 | +11.1% | 0.00% | -50.0% |
| Q2 2021 | $764,000 | +14.4% | 89,750 | +19.0% | 0.00% | 0.0% |
| Q1 2021 | $668,000 | -2.8% | 75,400 | +34.9% | 0.00% | 0.0% |
| Q4 2020 | $687,000 | +64.7% | 55,900 | +9.2% | 0.00% | +100.0% |
| Q3 2020 | $417,000 | +10325.0% | 51,200 | +12700.0% | 0.00% | – |
| Q2 2020 | $4,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,787,091 | $20,462,000 | 6.02% |
| INTERWEST VENTURE MANAGEMENT CO | 1,599,592 | $18,315,000 | 3.89% |
| NEXTHERA CAPITAL LP | 263,600 | $3,018,000 | 1.54% |
| SPHERA FUNDS MANAGEMENT LTD. | 385,301 | $4,412,000 | 0.86% |
| RA Capital Management | 354,200 | $4,056,000 | 0.50% |
| DAFNA Capital Management LLC | 35,977 | $412,000 | 0.35% |
| Boxer Capital, LLC | 138,331 | $1,584,000 | 0.35% |
| SABBY MANAGEMENT, LLC | 238,907 | $2,735,000 | 0.15% |
| Monashee Investment Management LLC | 31,500 | $361,000 | 0.14% |
| Lombard Odier Asset Management (USA) Corp | 100,000 | $1,145,000 | 0.11% |